Keros Therapeutics's total assets for Q4 2024 were $615.89M, an increase of 6.32% from the previous quarter. KROS total liabilities were $44.33M for the fiscal quarter, a -4.53% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.